ArticleAnnals of neurology2014
Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma.
Article in Annals of neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Pediatric Optic Pathway Gliomas: Diagnosis, Management, and Outcomes.International ophthalmology clinics · 2026Review
- Accounting for Biological Sex and Gender Identity in the Pathogenesis, Artistic Depictions, and Quality of Life in Neurofibromatosis Type 1.JID innovations : skin science from molecules to population health · 2025Review
- Genetics and current research models of Mendelian tumor predisposition syndromes with ocular involvement.Progress in retinal and eye research · 2025Review
- An Overview of Optic Pathway Glioma With Neurofibromatosis Type 1: Pathogenesis, Risk Factors, and Therapeutic Strategies.Investigative ophthalmology & visual science · 2024Review
- Estrogen-induced glial IL-1β mediates extrinsic retinal ganglion cell vulnerability in murine Nf1 optic glioma.Annals of clinical and translational neurology · 2024Article
- Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe Consortium.Molecular neurodegeneration · 2023Review
- Neurofibromatosis Type 1-Associated Optic Pathway Gliomas: Current Challenges and Future Prospects.Cancer management and research · 2023Review
- Targeted Therapies for the Neurofibromatoses.Cancers · 2021Review
- Optic pathway glioma and the sex association in neurofibromatosis type 1: a single-center study.Orphanet journal of rare diseases · 2021Article
- Neurofibromatosis 1-associated optic pathway gliomas.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2020Article
- Article
- Review
- Pediatric malignancies in neurofibromatosis type 1: A population-based cohort study.International journal of cancer · 2019Article
- Review
- Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.Journal of neuroscience research · 2019Review
- Optic Pathway Gliomas in Neurofibromatosis Type 1.Journal of child neurology · 2018Review
- Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2017Review
- Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future.Journal of the National Cancer Institute · 2017Review
- CNS Tumors in Neurofibromatosis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Review
- Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology.The Journal of experimental medicine · 2017Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
24740685What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.